Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy

American Journal of Kidney Diseases

Volumn 35, Issue 2, 2000, Pages 194-201

  Shoji, Tatsuya ^a,b   Nakanishi, Isao ^a,b   Suzuki, Akira ^a,b   Hayashi, Terumasa ^a,b   Togawa, Masaki ^a,b   Okada, Noriyuki ^a,b   Imai, Enyu ^a,b   Hori, Masatsugu ^a,b   Tsubakihara, Yoshiharu ^a,b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Corticosteroid; Immunoglobulin A (IgA) nephropathy; Prospective, randomized, controlled study; smooth muscle actin ( SMA)

Indexed keywords

ALPHA ACTIN; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; DIPYRIDAMOLE; FIBRONECTIN; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; MALE; MESANGIUM; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0033978462     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(00)70326-X     Document Type: Article

References (36)

1. G D'Amico The commonest glomerulonephritis in the world: IgA nephropathy Q J Med 64 1987 709 727
2. FP Schena A retrospective analysis of the natural history of primary IgA nephropathy worldwide Am J Med 89 1990 209 215
3. D Chauveau D Droz Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital Contrib Nephrol 104 1993 1 5
4. JH Galla IgA nephropathy Kidney Int 47 1995 377 387
5. CA Peh AR Clarkson Treatment of IgA nephropathy Nephrol Dial Transplant 10 1995 1119 1121
6. MG Radford Jr JV Donadio Jr EJ Bergstralh JP Grande Predicting renal outcome in IgA nephropathy J Am Soc Nephrol 8 1997 199 207
7. M Haas Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases Am J Kidney Dis 29 1997 829 842
8. A Koyama M Igarashi M Kobayashi Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases Am J Kidney Dis 29 1997 526 532
9. N Yoshikawa H Ito H Nakamura Prognostic indicators in childhood IgA nephropathy Nephron 60 1992 60 67
10. H Sakai K Abe Y Kobayashi A Koyama H Shigematsu T Harada N Yoshikawa M Arakawa H Itoh G Osawa O Sakai K Dohi N Yamanaka T Nagasawa K Kurokawa Clinical guidelines of IgA nephropathy Nippon Jinzo Gakkai Shi 37 1995 417 421
11. N Yoshikawa H Ito T Sakai Y Takekoshi M Honda M Awazu K Ito K Iitaka Y Koitabashi K Yamaoka K Nakagawa H Nakamura S Matsuyama Y Seino N Takeda S Hattori M Ninomiya A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy J Am Soc Nephrol 10 1999 101 109
12. C Pozzi PG Bolasco GB Fogazzi S Andrulli P Altieri C Ponticelli F Locatelli Corticosteroids in IgA nephropathy: A randomised controlled trial Lancet 353 1999 883 887
13. SL Friedman Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies N Engl J Med 328 1993 1828 1835
14. K Zhang MD Rekhter D Gordon SH Phan Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study Am J Pathol 145 1994 114 125
15. CE Alpers KL Hudkins AM Gown RJ Johnson Enhanced expression of “muscle-specific” actin in glomerulonephritis Kidney Int 41 1992 1134 1142
16. G Gabbiani The biology of the myofibroblast Kidney Int 41 1992 530 532
17. T Yamamoto NA Noble DE Miller WA Border Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis Kidney Int 45 1994 916 927
18. C Viedt A Burger GM Hansch Fibronectin synthesis in tubular epithelial cells: Up-regulation of the EDA splice variant by transforming growth factor beta Kidney Int 48 1995 1810 1817
19. Y Isaka Y Fujiwara S Yamamoto S Ochi S Shin T Inoue K Tagawa T Kamada N Ueda Modified plasma clearance technique using nonradioactive iothalamate for measuring GFR Kidney Int 42 1992 1006 1011
20. O Skalli P Ropraz A Trzeciak G Benzonana D Gillessen G Gabbiani A monoclonal antibody against alpha-smooth muscle actin: A new probe for smooth muscle differentiation J Cell Biol 103 1986 2787 2796
21. L Borsi B Carnemolla P Castellani C Rosellini D Vecchio G Allemanni SE Chang J Taylor-Papadimitriou H Pande L Zardi Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells J Cell Biol 104 1987 595 600
22. Y Kobayashi Y Hiki T Kokubo A Horii S Tateno Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study Nephron 72 1996 237 242
23. G D'Amico A Ragni E Gandini G Fellin Typical and atypical natural history of IgA nephropathy in adult patients Contrib Nephrol 104 1993 6 13
24. I Darby O Skalli G Gabbiani Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing Lab Invest 63 1990 21 29
25. RJ Johnson J Floege A Yoshimura H Iida WG Couser CE Alpers The activated mesangial cell: A glomerular “myofibroblast”? J Am Soc Nephrol 2 suppl 2 1992 S190 S197
26. DS Goumenos CB Brown J Shortland AM el Nahas Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Transplant 9 1994 1418 1425
27. Y Ando T Moriyama M Miyazaki Y Akagi N Kawada Y Isaka M Izumi K Yokoyama A Yamauchi M Horio A Ando N Ueda K Sobue E Imai M Hori Enhanced glomerular expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy Nephrol Dial Transplant 13 1998 1168 1175
28. G Remuzzi P Ruggenenti A Benigni Understanding the nature of renal disease progression Kidney Int 51 1997 2 15
29. C Zoja R Donadelli S Colleoni M Figliuzzi S Bonazzola M Morigi G Remuzzi Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation Kidney Int 53 1998 1608 1615
30. F Locatelli LD Vecchio C Pozzi The patient with IgA glomerulonephritis—What is the role of steroid treatment? Nephrol Dial Transplant 14 1999 1057 1060
31. MK Chan SY Kwan KW Chan CK Yeung Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis Am J Kidney Dis 9 1987 417 421
32. I Giatras J Lau AS Levey Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group Ann Intern Med 127 1997 337 345
33. JV Donadio Jr EJ Bergstralh KP Offord DC Spencer KE Holley A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group N Engl J Med 331 1994 1194 1199
34. GH Guyatt DL Sackett DJ Cook Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group JAMA 271 1994 59 63
35. R Sinniah AR Javier G Ku The pathology of mesangial IgA nephritis with clinical correlation Histopathology 5 1981 469 490
36. T Taguchi DB von Bassewitz S Takebayashi T Harada A comparative study of IgA nephritis in Japan and Germany. An approach to its geopathology Pathol Res Pract 182 1987 358 367